KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Optimal Timing of Surgery Following Neoadjuvant Therapy for Surgical and Oncological Outcomes in Advanced Esophageal Squamous Cell Carcinoma: An Exploratory Analysis of JCOG1109.

Ryosuke Kita, Ken Kato, Ryunosuke Machida, Yoshinori Ito, Hiroyuki Daiko, Hirofumi Kawakubo, Keita Sasaki, Haruhiko Fukuda, Yasue Kimura, Kohei Akiyoshi, Kazuo Koyanagi, Hiroki Hara, Keiko Minashi, Kenji Amagai, Tetsuya Abe, Satoru Matsuda, Takahiro Tsushima, Hiroya Takeuchi

Ann Surg Oncol 33(6) 5327-5338

PMID41535566
PMCIDPMC13179169
DOI10.1245/s10434-025-19050-6
发表日期2026-01-14
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

BACKGROUND: The optimal timing of surgery following neoadjuvant therapy in esophageal squamous cell carcinoma (ESCC) remains uncertain. This exploratory analysis aims to assess the impact of time to surgery (TTS) on perioperative and survival outcomes in patients with advanced ESCC enrolled in the phase III trial JCOG1109. METHODS: Patients who underwent esophagectomy following neoadjuvant chemotherapy or chemoradiotherapy were included. Within each treatment arm, patients were categorized into four TTS subgroups according to cohort quartiles. Perioperative complications, overall survival (OS), and progression-free survival (PFS) were evaluated. RESULTS: The median TTS was 35 (range, 16-81), 38 (17-109), and 41 (14-98) days for the cisplatin plus fluorouracil (CF), docetaxel, cisplatin plus fluorouracil, and CF with radiotherapy (CF-RT) arms, respectively. Baseline characteristics were comparable across the TTS subgroups. Operative time and overall complication rates showed no significant differences. In the CF-RT arm, a longer TTS was associated with increased blood loss (200, 210, 300, and 370 mL) and a trend toward a higher anastomotic leakage (6%, 7%, 14%, and 18%), as well as a trend toward poorer PFS and OS, particularly at more prolonged intervals. However, across all treatment arms, OS and PFS did not differ among the TTS subgroups, with multivariable analysis revealing no consistent associations between TTS and survival. CONCLUSIONS: Time to surgery following neoadjuvant therapy did not significantly influence prognosis in advanced ESCC. Nonetheless, prolonged intervals after chemoradiotherapy may increase surgical complexity and leakage risk, in addition to elevating the potential for adverse prognostic effects associated with excessive delays.

KM 提取结果

3 个 Figure · 8 个 KM 面板

进入结果中心
KM Figure3 个面板

Fig. 1

Fig. 1 Overall survival in the TTS subgroups. Kaplan–Meier curves for overall survival according to quartiles (Q1–Q4) in each treatment arm, with patients stratified into four subgroups within each treatment arm on the basis of TTS distribution quantiles in the overall cohort. a CF arm, b DCF arm, and c CF-RT arm. CF cisplatin plus fluorouracil; DCF docetaxel, cisplatin plus fluorouracil; CF-RT CF with radiotherapy

A

Overall survival

Fig. 1 · Panel A

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel A 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 4 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 3:extreme jump
查看结果
B

Overall survival

Fig. 1 · Panel B

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel B 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
C

Overall survival

Fig. 1 · Panel C

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel C 是同一 Fig. 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure3 个面板

Fig. 2

Fig. 2 Progression-free survival in the TTS subgroups. Kaplan–Meier curves for progression-free survival according to quartiles (Q1–Q4) in each treatment arm. a CF arm, b DCF arm, and c CF-RT arm. CF cisplatin plus fluorouracil; DCF docetaxel, cisplatin plus fluorouracil; CF-RT CF with radiotherapy

A

Progression-free survival

Fig. 2 · Panel A

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel A 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 4:short span
查看结果
B

Progression-free survival

Fig. 2 · Panel B

quality_warning 待 EXE 对齐 预期 4 条 已提取 3 条

Panel B 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线缺失:预期 4 条,实际恢复 3 条疑似重复轨迹:同一条 KM 曲线可能被重复识别曲线 3:extreme jump
查看结果
C

Progression-free survival

Fig. 2 · Panel C

complete 待 EXE 对齐 预期 4 条 已提取 4 条

Panel C 是同一 Fig. 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似图例或人工水平线:轨迹出现不合理的共同平台疑似图例或人工水平线:轨迹出现不合理的共同平台曲线 1:extreme jump
查看结果
KM Figure2 个面板

Fig. 3

Fig. 3 Overall survival and progression-free survival comparing the Q1-Q3 and Q4 TTS subgroups in the CF-RT arm. Kaplan–Meier curves for overall survival and progression-free survival in the CF-RT arm, comparing patients in the Q1–Q3 TTS subgroups with those in the Q4 subgroup. CF-RT cisplatin plus fluorouracil with radiotherapy

A

Overall survival

Fig. 3 · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

Progression-free survival

Fig. 3 · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 Fig. 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果